• 1
    Denardo SJ, Messerli FH, Gaxiola E, et al. Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]). Am J Cardiol. 2010;106:498503.
  • 2
    Bangalore S, Messerli FH, Wun CC, et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J. 2010;31:28972908.
  • 3
    Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006;144:884893.
  • 4
    Sleight P, Redon J, Verdecchia P, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009;27:13601369.
  • 5
    Denardo SJ, Gong Y, Nichols WW, et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am J Med. 2010;123:719726.
  • 6
    D’Agostino RB, Belanger AJ, Kannel WB, et al. Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham study. BMJ. 1991;303:385389.
  • 7
    Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;1:581584.
  • 8
    Fletcher AE, Beevers DG, Bulpitt CJ, et al. The relationship between a low treated blood pressure and IHD mortality: a report from the DHSS Hypertension Care Computing Project (DHCCP). J Hum Hypertens. 1988;2:1115.
  • 9
    Waller PC, Isles CG, Lever AF, et al. Does therapeutic reduction of diastolic blood pressure cause death from coronary heart disease? J Hum Hypertens. 1988;2:710.
  • 10
    Farnett L, Mulrow CD, Linn WD, et al. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA. 1991;265:489495.
  • 11
    Ruiz Ortiz M, Romo E, Mesa D, et al. Prognostic value of resting heart rate in a broad population of patients with stable coronary artery disease: prospective single-center cohort study. Rev Esp Cardiol. 2010;63:12701280.
  • 12
    Fernández Palomeque C, Bordají Mayor JL, Concha Ruiz M, et al. Clinical practice guidelines of the Spanish Society of Cardiology on stable angina. Rev Esp Cardiol. 2000;53:967996.
  • 13
    Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J. 1997;18:394413.
  • 14
    Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (Committee on the Management of Patients With Chronic Stable Angina). Circulation. 2003;107:149158.
  • 15
    Messerli FH, Panjrath GS. The J-curve between blood pressure and coronary artery disease or essential hypertension. Exactly how essential? J Am Coll Cardiol. 2009;54:18271834.
  • 16
    Protogerou AD, Safar ME, Iaria P, et al. Diastolic blood pressure and mortality in the elderly with cardiovascular disease. Hypertension. 2007;50:172180.
  • 17
    Tuomilehto J, Ryynanen OP, Koistinen A, et al. Low diastolic blood pressure and mortality in a population-based cohort of 16913 hypertensive patients in North Karelia, Finland. J Hypertens. 1998;16:12351242.
  • 18
    Kannel WB, Wilson PW, Nam BH, et al. A likely explanation for the J-curve of blood pressure cardiovascular risk. Am J Cardiol. 2004;94:380384.
  • 19
    Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345:479486.
  • 20
    Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:11051187.
  • 21
    Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:25602572.
  • 22
    Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28:88136.
  • 23
    Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14(Suppl 2):S1S113.
  • 24
    Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:21212158.
  • 25
    Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:15751585.
  • 26
    Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:6168.
  • 27
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:17551762.
  • 28
    Cruickshank JM. Antihypertensive treatment and the J-curve. Cardiovasc Drugs Ther. 2000;14:373379.